Zydus gains tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg
Ibrutinib tablets had annual sales of $ 2148.9 mn in the United States (IQVIA MAT May 2025)
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
chronic lymphocytic leukaemia
AztraZeneca to launch oncology drug Calquence in India
It is used to treat mantle cell lymphoma and chronic lymphocytic leukaemia
Janssen gets EC approval for expanded use of IMBRUVICA (ibrutinib) plus rituximab to treat CLL
Data from Phase 3 E1912 study showed previously untreated patients aged 70 years or younger treated with ibrutinib plus rituximab…
US FDA approves Novartis Kesimpta (ofatumumab) for relapsing forms of MS treatment
Ofatumumab was first approved by the FDA in 2009 for the treatment of chronic lymphocytic leukaemia (CLL)